Monte Rosa Therapeutics and Roche have signed a strategic collaboration and licensing agreement for the discovery and development of molecular glue degraders (MGDs) to target cancer and neurological diseases.
The partnership intends to combine Monte Rosa’s QuEENT discovery engine with Roche’s expertise in providing therapies to patients.
Go deeper with GlobalData
Monte Rosa will receive $50m as an upfront payment, with the potential to earn additional payments exceeding $2bn based on preclinical, clinical, commercial and sales milestones, along with tiered royalties.
The parties also agreed to broaden their collaboration across multiple targets in the first two years.
Additional payments will be made for nominations and for preclinical, clinical, commercial and sales milestones, in addition to tiered royalties on the products that result.
Monte Rosa will be responsible for discovery and preclinical activities against selected cancer and neurological diseases.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataRoche holds exclusive rights to advance the compounds through preclinical and clinical development, while Monte Rosa has complete ownership of its pipeline programmes.
Monte Rosa Therapeutics CEO Markus Warmuth stated: “Our QuEEN discovery engine, a highly validated and industry-leading molecular glue degrader platform, has been the cornerstone for Monte Rosa’s success, driving the discovery and development of our exquisitely selective MGDs successfully into the clinic.
“This collaboration will enable and accelerate the expansion of our platform into neuroscience and additional areas of oncology. We believe our decision to partner with Roche, a company that shares our vision and drive, will amplify our collective strengths and capabilities to accelerate the development of transformative treatments for patients across several indications.”
